Avience Biomedicals (NSE:AVIENCE) Ending Cash Position: ₹42.0 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AVIENCE Avience Biomedicals Ltd NSE:AVIENCE
18 GF Score
Price ₹250.90
! 3 Warning Signs
View Full Analysis

What is Avience Biomedicals Ending Cash Position?

Avience Biomedicals NSE:AVIENCE +1.17% 18 Ending Cash Position is ₹42.0 Mil as of Mar. 2025. GuruFocus rates NSE:AVIENCE with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Avience Biomedicals's Ending Cash Position for the quarter that ended in Mar. 2025 was ₹42.0 Mil.

Avience Biomedicals's quarterly Ending Cash Position increased from Mar. 2023 (₹0.9 Mil) to Mar. 2024 (₹1.5 Mil) and increased from Mar. 2024 (₹1.5 Mil) to Mar. 2025 (₹42.0 Mil).

Avience Biomedicals's annual Ending Cash Position increased from Mar. 2023 (₹0.9 Mil) to Mar. 2024 (₹1.5 Mil) and increased from Mar. 2024 (₹1.5 Mil) to Mar. 2025 (₹42.0 Mil).

Avience Biomedicals Ending Cash Position Related Terms

Avience Biomedicals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Avience Biomedicals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avience Biomedicals Ending Cash Position Chart

Avience Biomedicals Annual Data
Trend Mar23 Mar24 Mar25
Ending Cash Position
0.91 1.46 42.00

Avience Biomedicals Semi-Annual Data
Mar23 Mar24 Mar25
Ending Cash Position 0.91 1.46 42.00
NSE:AVIENCE
18GF Score
Avience Biomedicals Ltd NSE:AVIENCE
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avience Biomedicals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Avience Biomedicals's Ending Cash Position for the fiscal year that ended in Mar. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1.457+40.541
=42.0

Avience Biomedicals's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1.457+40.541
=42.0

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ₹42.0 Mil mean?
Avience Biomedicals (NSE:AVIENCE) has a Ending Cash Position of ₹42.0 Mil as of Mar. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Avience Biomedicals and its competitors.
Is Avience Biomedicals' Ending Cash Position too high?
Avience Biomedicals' current Ending Cash Position is ₹42.0 Mil. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' Ending Cash Position compare to ABT and SYK?
Avience Biomedicals' Ending Cash Position of ₹42.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Avience Biomedicals and its competitors. Avience Biomedicals's current Ending Cash Position is ₹42.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current Ending Cash Position of ₹42.0 Mil. The current Ending Cash Position is ₹42.0 Mil. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current Ending Cash Position is ₹42.0 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avience Biomedicals Business Description

Address C-11, Block-C, Community Centre, Unit No-2, 1st Floor, Janakpuri A-3, New Delhi, IND, 110058
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score

Get the complete analysis for NSE:AVIENCE

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹250.90
Price